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ABSTRACT
Objective: To systematically identify and summarise
the literature on perceived life expectancy among
individuals with non-cancer chronic disease.
Setting: Published and grey literature up to and
including September 2016 where adults with
non-cancer chronic disease were asked to estimate
their own life expectancy.
Participants: From 6837 screened titles, 9 articles
were identified that met prespecified criteria for
inclusion. Studies came from the UK, Netherlands and
USA. A total of 729 participants were included (heart
failure (HF) 573; chronic obstructive pulmonary disease
(COPD) 89; end-stage renal failure 62; chronic kidney
disease (CKD) 5). No papers reporting on other lung
diseases, neurodegenerative disease or cirrhosis were
found.
Primary and secondary outcome measures:
All measures of self-estimated life expectancy were
accepted. Self-estimated life expectancy was compared,
where available, with observed survival, physician-
estimated life expectancy and model-estimated life
expectancy. Meta-analysis was not conducted due to
the heterogeneity of the patient groups and study
methodologies.
Results: Among patients with HF, median self-
estimated life expectancy was 40% longer than
predicted by a validated model. Outpatients receiving
haemodialysis were more optimistic about prognosis
than their nephrologists and overestimated their chances
of surviving 5 years. Patients with HF and COPD were
approximately three times more likely to die in the next
year than they predicted. Data available for patients with
CKD were of insufficient quality to draw conclusions.
Conclusions: Individuals with chronic disease may
have unrealistically optimistic expectations of their
prognosis. More research is needed to understand how
perceived life expectancy affects behaviour. Meanwhile,
clinicians should attempt to identify each patient’s
prognostic preferences and provide information in a
way that they can understand and use to inform their
decisions.
Trial registration number: CRD42015020732.
INTRODUCTION
How long an individual expects to live—their
perceived life expectancy—reﬂects their
disease understanding and the medical pro-
fession’s ability to prognosticate for and com-
municate with them. Perceived life
expectancy may affect a variety of outcomes,
including healthcare choices. Patients with
incurable lung and colon cancer who
thought they were going to live for at least
6 months were more likely to favour life-
extending therapy over comfort care com-
pared with patients who thought there was at
least a 10% chance that they would not live
6 months.1 Critically unwell inpatients who
do not expect to live 2 months are less likely
to opt for cardiopulmonary resuscitation in
the event of sudden death than individuals
who perceive their prognosis to be better.2
Prognosis communication has been widely
studied in oncology, and the majority of
people with cancer want detailed prognostic
information, presented honestly and openly.3
However, non-cancer chronic disease causes
more deaths than cancer worldwide, with
cardiovascular disease being the biggest
killer.4 Almost 2.3 million people in the UK
have a diagnosis of coronary heart disease,
and over half a million have heart failure
(HF).5 An estimated 1.2 million people have
a diagnosis of chronic obstructive pulmonary
disease (COPD)6 and almost 60 000 receive
renal replacement therapy for end-stage
Strengths and limitations of this study
▪ This is the first review of perceived life expect-
ancy among patients with chronic non-cancer
disease.
▪ The findings build on and reproduce the oncol-
ogy literature showing patients with cancer have
a tendency to overestimate their life expectancy
and chances of cure.
▪ The findings of this review are based on the
small number of studies that have been con-
ducted on this subject.
▪ The literature was only available for patients with
heart failure, end-stage renal failure and chronic
obstructive pulmonary disease.
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renal failure (ESRF).7 Life expectancy for patients with
chronic disease including advanced COPD, HF and ESRF
can be as poor as that seen in incurable cancer.8–10
Lately, there has been a practice shift away from pater-
nalistic medicine. Shared decision-making empowers
individuals and their carers to make choices about what
care they want based on honest, open disclosure of the
known beneﬁts and risks of proposed treatment
options.11 Decisions to accept treatment with invasive
therapies such as ventilation, dialysis and implanted
cardiac deﬁbrillator placement may be inﬂuenced by
how long individuals expect to live. Patients facing such
decisions can only be considered fully informed if they
have an understanding of their prognosis and the effects
available treatments might have on it. Up to 38% of
patients near the end of life receive treatment adminis-
tered with little or no hope of it having any effect,
largely because of the underlying state of the patient’s
health and the known or expected poor prognosis
regardless of treatment.12 Quality of end-of-life care is
signiﬁcantly better for patients with cancer than for
patients with ESRF or HF, largely due to higher rates of
palliative care review and lower rates of intensive care
admission and cardiopulmonary resuscitation among
individuals with malignancy.13 It is possible that subopti-
mal end of life treatment is partly driven by unrealistic
expectations of prognosis.
Many patients with cancer, including those with incur-
able disease, report never discussing prognosis with their
healthcare team, misunderstand whether their condition
is curable and overestimate their expected survival.3 No
systematic analysis of perceived life expectancy among
individuals with non-cancer chronic disease has been
performed. This review was conducted to evaluate what
is known about how long patients with non-cancer
chronic disease expect to live and how these estimates
compare with other methods of predicting survival and
measured outcomes.
METHODS
Search strategy
A systematic search of MEDLINE, Embase, PsychINFO
and the Cochrane Library was conducted up to and
including September 2016. Abstracts of unpublished
works were searched using ProQuest dissertations and
theses search and the Networked Digital Library of
Theses and Dissertations Global ETD search. Search
terms relating to ‘life expectancy’ and ‘self-estimated’
were used (see online supplementary appendix A).
Search results were limited to humans and English
language.
Inclusion and exclusion criteria
Non-cancer chronic disease was deﬁned as any long-
term illness that is associated with reduced life expect-
ancy, but not caused by cancer or infection. Conditions
included were HF; chronic kidney disease stage 5
(CKD); ESRF receiving dialysis or conservative care; dia-
betes mellitus; COPD; interstitial lung disease; neurode-
generative disease and liver cirrhosis. Studies were
included where adults (≥18 years of age) with these con-
ditions were asked to estimate their life expectancy. All
measurements of life expectancy were accepted, includ-
ing those in terms of duration (eg, “How long do you
expect to live”), and chance (eg, “What is the chance
you will be alive in ﬁve years”). Studies were excluded
where only self-estimated probability of ‘cure’ was deter-
mined, where the only option for survival duration was
<6 months and where participants were asked to con-
sider only hypothetical situations (eg, “How long do you
think you would live if you had a kidney transplant”).
Studies reporting only on participants with cancer,
HIV/AIDS, congenital heart disease, cystic ﬁbrosis and
organ transplant were excluded. In all these conditions
the situation, illness culture or advances in treatment
may have affected how generalisable ﬁndings were to
the larger chronic disease population. At the title and
abstract searching phase, articles assessing prognosis in
excluded diagnoses were not rejected, so that reference
list searches could be performed from these papers.
Where studies reported a mixture of included and
excluded diagnoses, they were incorporated if the data
on individual diseases were reported separately. Where
data were not separately reported, authors were con-
tacted to request online supplementary ﬁles. Data were
extracted from ﬁgures and tables in papers, where
needed.
Study selection process
Titles were independently examined by two reviewers
(BH and JS) according to the above criteria and a
Kappa statistic calculated to assess agreement. Abstracts
from titles accepted by either one or both reviewers
were collected and assessed independently, using the
same criteria, and included if both recommended inclu-
sion. Where only one reviewer recommended inclusion,
a consensus decision was made after discussion. Full text
articles were requested and read and reference lists were
examined with additional papers included by the same
criteria. At this point, papers reporting excluded disease
groups were rejected. Disagreement between authors
was addressed by discussion and a consensus decision
reached in all cases.
Quality assessment
No suitable tool to grade the quality of included litera-
ture could be found. A quality assessment tool (see
online supplementary appendix B) was developed by
the authors to assess and grade the quality of available
literature based on semiobjective assessment of factors
inﬂuencing the generalisability, risk of bias and report-
ing quality of included literature. This tool has not been
previously validated. Papers included for review were
independently graded by the authors and a mean score
taken to categorise each as low, medium or high quality.
2 Hole B, Salem J. BMJ Open 2016;6:e012248. doi:10.1136/bmjopen-2016-012248
Open Access
group.bmj.com on July 21, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
The study was registered with the PROSPERO database,
registration number CRD42015020732.
RESULTS
The initial search provided 6837 titles after removal of
duplicates. 249 abstracts were selected for review by
either one or both authors (agree to exclude, 6588;
agree include, 158; disagree, 91; κ 0.77). Thirty-one arti-
cles were collected, and reference list searching pro-
vided an additional eight. After full text examination of
39 articles, seven papers and two conference abstracts
were included in the review (ﬁgure 1). No unpublished
works met the inclusion criteria. Two of the included
papers originate from a single study.14 15 A complete list
of papers including reasons for inclusion/rejection is
available (see online supplementary appendix C).
Evidence was graded as medium quality in four and low
quality in three of the included papers (table 1). No arti-
cles were graded as high quality. The two abstracts were
not quality assessed as insufﬁcient information was
available.
Studies came from the UK,18 Netherlands17 and
USA.14 16 19–22 A total of 729 participants were included
(HF, 573; COPD, 89; ESRF, 62; CKD, 5) with study sizes
ranging from 20 to 135 patients (see table 1). Four
papers reported on a single medical disease;
HF16 17 19 21 22 and ESRF.20 Others reported on a
mixture of conditions; HF and COPD14 15 and HF, CKD
and COPD.18 No papers reporting on non-COPD lung
disease, neurodegenerative disease or cirrhosis were
found.
The mean age of study participants ranged from 58 to
75. In the study by Fried et al14 15 only individuals over
60 years of age were recruited and only those over 50 in
the study by Kraai et al.17 No minimum age was set in
the other studies. Two studies did not include selection
criteria for disease severity,16 17 and selection criteria
were unreported in one study.21 In all other studies, cri-
teria were used to select for patients with advanced
disease. Patients with ESRF were all receiving outpatient
haemodialysis.20 Reported levels of comorbidity were
high. The mean Charlson Comorbidity Index for
patients with ESRF was 5.8 (SD 1.6).20 Among US
patients with HF in one study, 82% had hypertension,
54% diabetes and 29% COPD.16 Among patients with
HF from the Netherlands, 57% had hypertension, 30%
had diabetes, 24% had COPD and 11% had a stroke.17
One study used a written questionnaire to measure
self-estimated life expectancy.19 Methodology was unre-
ported in two studies.21 22 All other studies used inter-
views. Participants with ESRF were asked about their
chances of being alive at different time points.20 In the
other studies, participants were asked to indicate how
long they expected to live by selecting from vignette
answers,18 giving a verbal response14–16 and/or by using
a Visual Analogue Scale.16 17 In one study, it was not pos-
sible to ascertain how the question had been posed or
answered.19 For studies where data were available, large
numbers of initially eligible patients were excluded from
Figure 1 PRISMA diagram.
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Table 1 Summary of included articles
Reference Conditions Origin Quality Design Patients included Measures used Results Summary Pros + and cons −
Allen et al16
2008
HF USA Medium Cross-sectional
interviewer-administered
questionnaire in a single
centre outpatient
heart-failure service
122 sequentially
recruited participants
with HF (NYHAI-IV)
Mean age 61 (IQR
53–74)
62% male
47%
African-American
1. Patients were asked “If
you had to guess, how
much longer do you
think you will live?” and
completed
A. Multichoice
answers ranging
from <3 months
to >10 years,
and
B. A visual
Analogue Scale,
marking their
estimated age at
death
2. Model-predicted life
expectancy using the
Seattle Heart Failure
Model
3. Observed survival over
median follow-up of
3 years
Median self-estimated life
expectancy was 13 years (IQR
8–21; range 1–54 years)
Median model-predicted life
expectancy was 10 years (IQR
7.2–13.3; range 2.0–25 years)
66% of patients overestimated
their survival compared with
the model by 30% or more
The median overestimate was
40%
29% of patients died within
3 years
Self-estimated-life
expectancy was on
average significantly
greater than that
predicted by a validated
model
Younger age, greater
disease severity and
measures of less
depression were
independently
associated with
overestimation of survival
+ Efforts made to
improve and check
patient understanding
of question
− 26 of 148 enrolled
participants felt unable/
unwilling to estimate
survival
− Only 35 of 122
patients were followed
up until their death
− Only 9 of 122
patients had NYHA IV
HF
− No index group
without chronic
disease was included
Fried et al15
2003
COPD
HF
USA Medium Cross-sectional interview
survey administered to
patients registered at
community practices and
outpatient clinics of two
hospitals, and inpatients of
three hospitals.
Same patient group as
Fried et al 2006
135 patients with
COPD or HF, aged
60 and older,
meeting criteria for
limited life
expectancy and
requiring assistance
with daily living
COPD—79 patients
Mean age 72 (SD 7)
51% Male
92% White
HF—56 patients
Mean age 75 (SD 8)
70% Male
88% White
Patients and clinicians
were asked how long they
thought the patient would
live and answered using
multichoice options
ranging from <1 month to
>10 years
Only 9 of 135 patients
expected to live <1 year, but
38 patients died over this
period.
58 of 79 patients who
responded to being asked to
estimate their own life
expectancy expected to live
2 years or more
Of the 65 available patient–
clinician pairs who both
responded, 34 agreed the
prognosis was 2 years or
more, 9 agreed the prognosis
was 2 years or less, 7
clinicians thought the patient
would live 2 years or more
when the patient did not
expect to live this long and 15
patients expected to live
2 years or more when their
clinician was less optimistic
Kappa was 0.22 suggesting
very poor agreement
Patient expectations of
1 year mortality are
higher than observed.
Agreement between
patients and their
clinicians about likely
prognosis is poor.
− 56 of 135 patients
were unable or
unwilling to estimate
their life expectancy
− No index group
without chronic
disease was included
Continued
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Table 1 Continued
Reference Conditions Origin Quality Design Patients included Measures used Results Summary Pros + and cons −
Fried et al14
2006
COPD
HF
USA Medium Serial interview survey
administered to patients
registered at community
practices and outpatient
clinics of two hospitals,
and inpatients of three
hospitals.
Same patient group as
Fried et al 2003
135 patients with
COPD or HF, aged
60 and older,
meeting criteria for
limited life
expectancy and
requiring assistance
with daily living
COPD—79 patients
Mean age 72 (SD 7)
51% Male
92% White
HF—56 patients
Mean age 75 (SD 8)
70% Male
88% White
Patients were asked how
long they thought the
patient would live and
answered using
multichoice options
ranging from <1 month to
>10 years
9 of 59 patients who
responded expected to live
<1 year at their first interview.
Of 59, 5 expected to live
<1 year at their final interview
38 of 135 patients died over
this period
Patient expectations of
1 year mortality are
higher than observed
The majority of patients
(those who were alive
and dead at the end of
the year-long study)
made no adjustment to
their self-estimated life
expectancy
− 56 of 135 patients
were unable or
unwilling to estimate
their life expectancy
− No index group
without chronic
disease was included
Kraai et al17
2013
HF The
Netherlands
Low Cross-sectional
questionnaire administered
in outpatient setting in one
HF clinic.
Subcomponent of time
trade-off study
100 patients with HF
(NYHA I–IV) all over
50 years of age.
Mean age 70 (SD
9.4)
71% male
Visual Analogue Scale
from 50 to 100 years of
age; patients were asked
to indicate the most
accurate estimation of their
life expectancy
Mean life expectancy indicated
by patients was 82 (SD 8.6)
years.
No difference in self-estimated
life expectancy was found
between patients unwilling vs
willing to trade time
Self-estimated life
expectancy probably
exceeds likely outcomes,
but no comparator data
was available.
Despite patients with
more advanced or
symptomatic HF being
more willing to trade
time, no difference was
found between the
groups in terms of
expected longevity
− No comparator
prediction or
measurement of
survival used
−Only 2 of 100
patients had NYHA IV
HF
− No index group
without chronic
disease was included
Shah et al18
2006
HF COPD
CKD
UK Low Cross-sectional
interviewer-administered
questionnaire in outpatient
and inpatient settings at
one acute NHS Trust and
a neighbouring hospice
20 patients in total
meeting criteria for
limited life
expectancy:6 HF
(NYHA III/IV)
9 COPD
5 CKD
Median age 72
50% male
85% white
Patients and physicians
chose one of seven short
prognosis statements that
most accurately predicted
how their illness might
affect their life expectancy
7 of 20 (35%) patients
estimated their prognosis to be
<1 year
13/17 physicians (76%)
estimated their patient’s
prognosis to be < 1 year
Exploratory study, no
firm conclusions
available
− Very small numbers
− Sample poorly
representative of a
general outpatient
population
− No index group
without chronic
disease was included
Stewart
et al19 2010
HF USA Low Cross-sectional written
questionnaire with
inpatients and outpatients
from two HF centres.
105 patients with
LVEF <35% and
symptomatic HF
Mean age 58 (SD
Methodology for collecting
self-estimated life
expectancy not described
65% thought they would live
more than 10 years and 34%
believed they would be alive
for at least 20 years.
Patients willing to trade more
Self-estimated life
expectancy probably
exceeds likely outcomes,
but no comparator data
was available.
− No comparator
prediction or
measurement of
survival
− Only 3 of 105
Continued
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Table 1 Continued
Reference Conditions Origin Quality Design Patients included Measures used Results Summary Pros + and cons −
Subcomponent of time
trade-off study.
13)
70% male
time expected shorter survival
than those unwilling to trade
time. 46% of the patients
willing to trade away at least
12 months anticipated that
they would not survive 5 years.
No difference was found in
self-estimated survival
between inpatients and
outpatients (data not provided)
Willingness to trade time
is associated with shorter
self-estimated life
expectancy
patients had NYHA IV
HF
− Study methodology
and tool not described
− No index group
without chronic
disease was included
Wachterman
et al20 2013
ESRF USA Medium Cross-sectional
interviewer-administered
questionnaire in two
community-based
haemodialysis units.
62 patients receiving
maintenance
haemodialysis with
20% or greater
predicted risk of
dying in the next
year.
Mean age 68 (SD
10)
42% Male
52% Black
1. Patients asked what
they thought their
chance was of being
alive at 1 and 5 years
(≥90%, about 75%,
about 50%, about
25%, ≤10%, don’t
know).
2. Nephrologist in charge
of care asked to
estimate each patients’
chance of being alive
at 1 and 5 years on a
continuous scale of 0%
to 100%.
3. Survival data with
follow-up of 23 months
For 1 year survival prediction,
patients were more optimistic
in 64% of patient–nephrologist
pairs, whereas nephrologists
were more optimistic in only
10%.
For 5 year survival prediction,
patients were more optimistic
in 69% patient–nephrologist
pairs, whereas nephrologists
were more optimistic in only
2%
Only 6% of patients thought
they had a <50% chance of
being alive at 5 years, whereas
actual survival at 23 months
was only 56%
Patient expectations of
5-year mortality are
higher than observed.
Patients were
significantly more
optimistic about their
survival than their
nephrologists.
Patients’ 1 year survival
expectations were more
consistent with actual
survival than clinician
estimates.
Patients who expected to
live longer were more
likely to opt for
life-extending treatments
− 88 of 150 eligible
patients were excluded
or refused to
participate
− No index group
without chronic
disease was included
Ambardekar
et al21 2016
(abstract only)
HF USA Not
rated
Cross-sectional report of
self-estimated life
expectancy. Methodology
not reported.
Subcomponent of
multicentre prospective
cohort study
161 ambulatory
patients with
advanced HF from
10 American centres
1. Patient
self-assessment of life
expectancy
2. Outcomes at mean
follow-up of 13 months
3. Methodology for data
collection not
described
64% of patients identified by a
physician to have ‘high-risk’
HF estimated a life expectancy
of >2 years.
40% died, were transplanted
or required a mechanical
left-ventricular assist device
over a mean follow-up of 13
months
Patients expectations of
outcome were optimistic
compared with
physician-predicted or
observed outcomes
+ Multicentre
prospective cohort
− Abstract only at time
of review
− No index group
without chronic
disease was included
O’Donnell
et al22 2015
(abstract only)
HF USA Not
rated
Self-assessment of
prognosis in single centre
cohort of hospitalised
patients with HF.
Methodology incompletely
reported
23 participants
Mean age 73
66% Male
77% White
Patient self-assessment of
life expectancy
70% of patients estimated a
life expectancy of >5 years
43% of patients estimated a
life expectancy of >10 years
Self-estimated life
expectancy probably
exceeds likely outcomes,
but no comparator data
were available.
Patients who did not
want to discuss
prognosis all expected to
live >10 years
− Very small numbers
− Abstract only at time
of review
CKD, Chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRF, end-stage renal failure; HF, heart failure; LVEF, left ventricular ejection fraction.
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the studies, largely on the grounds of language skills or
cognitive impairment (range: 88/150 (59%);20 82/238
(34%);17 82/361 (23%);14 15 4/44 (9%))18. Some parti-
cipants were unable or unwilling to provide a self-
estimate of life expectancy (range: 56/135 (41%);14 15
26/148 (18%);16 3/62 (5%);14 15 20 0/40 (0%)).18
Self-estimates of life expectancy were compared with
predictions from clinical risk calculators,16 clinician-
estimated life expectancy,14 15 18 20 observed survival14–16 18
20 21 or presented without comparator data.17 19 22
Follow-up periods ranged from 1 to 3 years, and the
majority of patients (range 56–73%) were alive at the
end of the studies. Analysis was performed in one study
to characterise factors associated with overestimation of
survival.16 In three papers, patients were asked about
their preferences around treatment aims, and analyses
performed looking at how these responses correlated
with self-estimated life expectancy.17 19 20 One paper
used repeat measures to examine how self-estimated life
expectancy changed with disease course.14
Self-estimated life expectancy compared with observed
survival
Comparisons of self-estimated life expectancy and
observed survival were reported in ﬁve papers from four
studies14–16 18 20 and one abstract.21 In general, self-
estimated life expectancy exceeded observed survival.
The only example of self-estimated life expectancy con-
sistent with survival was 1-year mortality in patients with
ESRF.20 81% of patients thought they had a better than
90% chance of being alive at 1 year. Observed survival
was 93%. In comparison, 96% of patients believed they
had a better than 50% chance of being alive at 5 years,
but 44% had died within just 23 months. In one study,
only 5% of patients with HF estimated their life expect-
ancy to be 3 years or less, but observed mortality was
29% after a median follow-up of 3.1 years.16 Among
patients with advanced HF, 3 of 56 (5%) patients
expected to live <1 year, but 17 (30%) were dead in this
period.15 Furthermore, 6 of 79 (8%) patients with
COPD in the same study predicted their life expectancy
to be <1 year; 21 (27%) died. When interviewed within
the 90 days before they died, only 2 of 16 patients pre-
dicted their life expectancy to be less than a year.14 In
the study published only as an abstract, 64% of patients
with HF expected to live for longer than 2 years, but at a
mean follow-up of 13 months 40% had died, been trans-
planted or required a left-ventricular assist device.21
Patient numbers were too low in one study to draw con-
clusions from observed survival.18
Self-estimated life expectancy compared with model
predictions of survival
In the only study that used a validated model23 to
predict survival, self-estimated life expectancy exceeded
model predictions.16 The median self-estimated life
expectancy for 122 patients with HF was 13 years and
the median model-predicted life expectancy was
10 years. There was no signiﬁcant relationship between
self and model-predicted life expectancy. The median
ratio between self-estimated and model-estimated life
expectancy was 1.4; indicating a 40% overestimation.
Self-estimates of life expectancy were more similar to
model predictions based on age and gender alone than
to predictions taking heart disease into account.
Self-estimated life expectancy compared with
clinician-estimated life expectancy
Four papers from three studies reported comparisons of
self-estimated and clinician-estimated life expect-
ancy.14 15 18 20 Estimates agreed poorly, with a tendency
for patients to be more optimistic about life expectancy
than their clinicians. Estimating 1-year and 5-year sur-
vival, patients with ESRF on dialysis were signiﬁcantly
more optimistic than their nephrologists.20 Among
patients with COPD and HF, agreement between
patients and their clinicians about whether the patient
would survive 2 years was poor, with a Kappa statistic of
0.22.15 Numbers of patients in one study were too small
for any conclusions to be drawn.18
Other findings
Younger age, greater disease severity and lower levels of
depression were independently associated with self-
estimated life expectancy exceeding model predictions
among patients with HF.16 Patients receiving haemodialy-
sis who thought they had a ≥90% chance of being alive
in 1 year were signiﬁcantly more likely to choose life-
extending therapy (44%) than patients who reported a
<90% chance (9%).20 Patients with advanced COPD and
HF serially interviewed over 1 year showed no evidence
of adjusting their self-estimated life expectancy with
disease progression.14 Only one patient of 135 revised
their estimate from >1 year to <1 year, while mortality
was 28% over this period. Three studies found that
patients with HF make estimates of their life expectancy
that are likely to be optimistic but did not present any
other validated prediction or measure of survival.17 19 22
One found patients who anticipated shorter survival to
be more willing to trade longevity for improved quality
of life than those who predicted longer lives.19 The
other study did not demonstrate this.17 One study was
published only as an abstract and had insufﬁcient
numbers of patients to draw conclusions.22
DISCUSSION
Practice guidelines advocate considering prognosis when
making decisions with patients who have chronic
disease24 25 and promote sharing survival statistics with
patients.26 27 There is evidence from cancer14 28 29 and
non-cancer15 30 31 literature that patients with life-limiting
illness want open and honest communication about their
prognosis. Where treatment options differ markedly in
survival beneﬁt, patients require an understanding of
their life expectancy with each treatment to make fully
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informed decisions between them. Hospitalised indivi-
duals are more likely to want cardiopulmonary resuscita-
tion if they expect to survive their illness, even if these
expectations are improbable.2 32 Patients with terminal
cancer who are optimistic about their prognosis are
more interventional in their choice of medical therapy.1
It is conceivable that behaviours as diverse as adherence
to preventative drugs and deciding whether to make a
will could be inﬂuenced by how long an individual
expects to live.
In this systematic review of self-estimated life expect-
ancy in chronic disease, individuals’ estimates exceeded
nearly all predictions and measures of survival; including
model-predicted and observed survival. Patients with
non-cancer chronic disease may have survival expecta-
tions that markedly exceed outcomes. These expecta-
tions might lead some patients to make health decisions
and life choices that they would not if their predictions
were more realistic. Patients were more optimistic than
their clinicians when estimating life expectancy. Only in
one instance (1 year survival in ESRF) were patients’ esti-
mations in keeping with actual survival, and more accur-
ate than their physicians’, but by 2 years this had
reversed.20 Whether this time-based effect represents a
reproducible feature of perceived versus clinician-
predicted life expectancy would require replication in
other disease groups. Patients with HF and COPD were
approximately three times more likely to be dead within
the year than they predicted.15 Life expectancy was over-
estimated by a median of 40% by patients with HF, when
compared with a validated model; equating to 3 years of
life for the average patient.16 Self-estimates were more in
keeping with the life expectancy of matched adults
without chronic disease.16 There was evidence that no
meaningful adjustment in expected survival is made by
patients approaching the ends of their lives.14
If the ﬁndings of this review reﬂect pervasive overesti-
mation of life expectancy by individuals with chronic
disease, there are several possible explanations. First,
patients might never be informed that their condition
could affect their life expectancy. Such individuals are
likely to base survival expectations on familial and media
exposure, inﬂuenced by hopefulness and ‘ﬁghting
spirit’. Others might receive overoptimistic forecasts;
either due to methods of estimation, or adjustment by
the communicating clinician. Finally, patients might be
provided with appropriate quantitative estimates, but
instead form more favourable personal predictions.
These ﬁndings are compatible with the oncology lit-
erature. Most patients with cancer want to discuss life
expectancy, although desire for quantitative estimation
varies.33 Despite this, many report not having discussed
prognosis or are found to misunderstand the status of
their disease, the aim of their treatment and their prog-
nosis.3 Overestimation of the chances of cure and sur-
vival is common, even if disease is incurable and where
individuals report having discussed prognosis with their
clinician.34 The prognosis in non-cancer disease can be
equivalently poor to that seen in malignancy.8–10 End of
life care differs by diagnosis, so caution must be taken
when generalising ﬁndings from cancer to non-cancer
disease settings.13 35
None of the patients with ESRF in this review recalled
discussing life expectancy with their clinician; their
nephrologists reported having such conversations with
only 3% of the patients.20 Sixty-three per cent of patients
with HF in one study did not recall having spoken with
their physician about their prognosis following the diag-
nosis of HF and only 36% believed HF would shorten
their life.16 Only 22% of patients in one study with
advanced COPD and HF recalled having been told that
they could die of their disease and only 1% recalled
having been given an estimate of how long they might
live.15 Prognostic discussions between patients with non-
cancer chronic disease and their clinicians may be infre-
quent. In a systematic review of the literature, it was
found that most patients with COPD report that they
have never had an end of life care discussion with a
healthcare provider.36 Interviews with individuals with
ESRF suggest that while early information is beneﬁcial,
the daily focus on clinical care and a reliance on clini-
cians to initiate end of life care discussions act as bar-
riers to advance planning.31 Interviews with patients with
ESRF and their clinicians suggest that nephrologists tend
to avoid discussions about the future.37 The evidence for
prognostic discussions between patients with cancer and
their clinicians is varied.3 Discussions are more likely to
be triggered by the clinician than the patient and are
probably infrequent among individuals with advanced
malignancy.3 Where discussions occur, they are often
unclear and both parties tend to avoid acknowledging or
discussing prognosis.38 There are boundaries to clini-
cians initiating prognostic discussions, such as fear of
causing anxiety or destroying hope;39 uncertainty about
the validity, accuracy or precision of estimates40 and lack
of experience and training in communication skills.41
A better understanding is needed of the interaction
between survival expectations and behaviour in chronic
disease. If compelling evidence is found showing over-
estimation of survival leads patients to make decisions
out of keeping with their likely future, approaches to
adjusting such expectations could be developed.
Inclusion of validated methods for estimating and com-
municating prognosis in decision support materials may
be one way of increasing the frequency of prognostic dis-
cussions. Research into the acceptability and best meth-
odology for facilitating these discussions should be a
research priority. Some patients will not feel able to
discuss prognosis, so clinicians must take care to eluci-
date preferences for information. However, clinicians
should continue to provide opportunities for prognostic
discussion, since preferences may change over time and
with disease progression. In other diseases such as breast
cancer, the use of prognostic models and decision tools
has been shown to increase understanding of prognosis
and treatment options, leading to higher degrees of
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satisfaction.42 Validated tools to help predict survival in
chronic disease are available,23 43–45 but there is no evi-
dence that these are widely employed. Only a minority
are provided with accessible calculators (box 1). Studies
are needed to examine how prognostic tools can be
used in the clinical setting.46 It is possible that clinical
practice has not kept pace with the paradigm shift
towards information sharing with patients. Even where
prognostic discussions happen, survival statistics may be
misrepresented or censored.47 In one study included in
this review, nephrologists provided estimates of life
expectancy for 89% of the interviewed patients, but
reported they would withhold over half of these esti-
mates in clinical practice.20
The ability to make ﬁrm conclusions from the litera-
ture was highly limited by the lack of available evidence.
The literature comes largely from single centre cohorts
and is of medium to low quality. Data from diseases
other than HF is extremely limited, and those with the
most advanced disease were under-represented.
Included studies are likely to have come from centres
where prognostication is considered important. We
excluded studies including only participants with cancer,
HIV/AIDS, congenital heart disease, cystic ﬁbrosis and
organ transplant. Cancer literature has been well sum-
marised,3 but it is possible that these excluded condi-
tions could have provided additional insight. We are
aware of only one paper that would have been included
without this exclusion, showing that young adults with
congenital heart disease expect to live almost as long as
their healthy peers.48
There is no standardised or validated method for
assessing self-estimated life expectancy, and it is likely
that responses are inﬂuenced by methodology.
Additionally, asking a patient how long they expect to
live facilitates a quantitative assessment of their under-
standing but does not provide information on how such
perceptions are formed and inﬂuenced. Large numbers
of patients were excluded from the studies or were
unable or unwilling to estimate their own life expect-
ancy, with the potential to introduce bias. In addition,
many patients were excluded on grounds of language
skills or cognitive impairment. These excluded indivi-
duals are likely to ﬁnd discussing and understanding
prognosis particularly challenging, and this undermines
the relevance of the included studies to a population of
patients with chronic disease, in whom cognitive impair-
ment is common. All the studies reporting actual sur-
vival were limited by short follow-up times and low
numbers of deaths in the cohorts. Hospitalised patients
were under-represented in the included studies. It is
feasible that survival expectations are different during
periods of acute illness requiring admission; the point at
which critical decisions about healthcare are often
made. There is evidence to suggest that overestimation
of survival persists in these situations however; in malig-
nant and non-malignant disease.2 32 34 49
None of the included studies had a healthy reference
group. Overestimation of life expectancy cannot, there-
fore, be presumed a phenomenon limited to patients
with disease. A recently published prospective cohort
study provides some evidence to suggest self-estimation
of survival might be different among individuals unse-
lected for chronic disease. Approximately half of partici-
pants made predictions of their life expectancy
consistent with those from a statistical model.50 Where
predictions were inaccurate, they were approximately
three times more likely to be underestimates than over-
estimates. Overestimation increased with age, but it is
unclear whether this represented an independent effect
of ageing on subjective life expectancy, or confounding
by the increased prevalence of disease. It is possible that
general population studies of self-estimated life expect-
ancy could be analysed for differences between indivi-
duals with and without disease.
CONCLUSIONS
Patients with non-cancer chronic disease may have sur-
vival expectations that markedly exceed outcomes.
These expectations might lead some patients to make
health decisions and life choices that they would not if
their predictions were more realistic. A better under-
standing is needed of the interaction between survival
expectations and behaviour in chronic disease. If com-
pelling evidence is found showing overestimation of sur-
vival leads patients to make decisions out of keeping
with their likely future, approaches to adjusting such
expectations could be developed. Meanwhile, clinicians
caring for patients with chronic disease must make
attempts to elucidate what prognostic information each
patient already knows, wants to know and might beneﬁt
from knowing. Appropriate information should then be
shared in a form that the patient can use to inform their
decisions.
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